NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Friday, September 8, 2023

7:30am – 5:05pm 

Earn up to 6.75 AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

Register Now

Location

National Institutes of Health
Natcher Conference Center
45 Center Drive
Building 45
Bethesda, MD 20892

Providers

Jointly Provided by National Institutes of Health and the North American Neuroendocrine Tumor Society.

NOTE TO ALL FEDERAL EMPLOYEES: A lunch will be avaialble during the conference to federal employees for $20.00. You must register for the lunch in advance.

Federal Employees Luncheon Registration

NETs Meet & Greet Reception

Join us, interact with other NET professionals, and mix and mingle with all of our appreciated event sponsors. NANETS will be hosting a reception for all Faculty presenters and attendees of the NIH Regional Conference. The reception is Thursday, September 7th from 6 pm-9 pm at the Rooftop Downtown Bethesda (located in the Hyatt) which is an indoor high-rise venue that boasts incredible views of the downtown Bethesda cityscape, featuring gorgeous floor-to-ceiling windows. There will be an open bar, and food stations available. 

*Your RSVP for the reception does NOT register you for the Regional Conference, please be sure to complete both forms if you would like to join us for the Meet & Greet Reception. You MUST be regsitered for the Regional Conference to attend. Spots are limited so RSVP today*

RSVP Now

 

Bethesda NET Regional Course Director

Jaydira Del Rivero, MD, National Institutes of Health

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
• Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
• Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
• Recognize the clinical features associated with carcinoid syndrome
• Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
• Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

NETs Meet & Greet Reception

RSVP Now

 

Program

• • James L. Gulley, MD, PhD, FACP, Co-Director Center for Immuno-Oncology, CCR, NCI, NIH & Clinical Director, National Cancer Institute, NIH

• • Introduction and Epidemiology of Neuroendocrine Tumors
    Julie Hallet, MD, MSC, FRCSC, Associate Scientist, Odette Cancer Center, Sunnybrook Health Sciences Centre
  • Radiological and Nuclear Medicine Imaging of Neuroendocrine Tumors: An Update for the Clinician
    Elcin Zan, MD. Assistant Professor of Clinical Radiology, Weill Cornell Medicine
  • Panel Question and Answers-Overview of NETs
    Moderated by Sandy Kotiah, MD, Director of The Neuroendocrine Tumor Center, Mercy Medical Center

• • Surgery and Perioperative Management in Small Bowel Neuroendocrine Tumors
    Julie Hallet, MD, MSC, FRCSC, Associate Scientist, Odette Cancer Center, Sunnybrook Health Sciences Centre
  • Surgical Management of Pancreatic Neuroendocrine Tumors: What Every Surgeon Needs to Know
    Callisia Clarke, MD, MS, FACS, FSSO. Associate Professor and Chief, Medical College of Wisconsin
  • Hepatic Cytoreductive Surgery for Neuroendocrine Tumors: What is the Threshold?
    James Howe, MD, FACS. Professor of Surgery-Surgical Oncology and Endocrine Surgery, Iowa University
  • Neoadjuvant/Adjuvant Therapy for NETs: Current and Future Approaches
    Heloisa Soares, MD, PhD. Associate Professor, Huntsman Cancer Center
  • Local Regional Therapies for Neuroendocrine Tumors: What the Interventional Oncologic Radiologist Can Offer
    Michael Kassin, MD, Staff Clinician, National Institutes of Health
  • Panel Question and Answers-Surgical Management
    Moderated by Jaydira Del Rivero, MD, Physician Scientist, Developmental Therapeutics Branch, National Institutes of Health

• • Indications of PRRT in Neuroendocrine Tumors: Current State and Future Directions
    Erik Mittra, MD, PhD, Nuclear Medicine Physician, Professor of Diagnostic Radiology, School of Medicine, Oregon Health & Science University
  • PRRT Related-Toxicities in Neuroendocrine Tumors: Prevention and Management
    Aman Chauhan, MD. Leader of the Neuroendocrine Tumor Program; Co-Director, Theragnostic Program, University of Miami
  • Panel Question and Answers-PRRT
    Moderated by Elcin Zan, MD. Assistant Professor of Clinical Radiology, Weill Cornell Medicine

• • Identifying and Addressing Gaps in Patient Care from Patient Support Groups, Clinical Care and Research Role of the Patient Support Groups in Neuroendocrine Tumors from the Perspective of the International Neuroendocrine Tumor Alliance (INCA) and Understanding Gaps in Patient Care - Ms. Stephanie Alband - PheoPara Alliance
  • Rare Cancers Research Program (RCRP) Overview: Funding Opportunities for Neuroendocrine Tumors- Dr. Sagar Ghosh – Congressionally Directed Medical Research Programs (CDMRP) Department of Defense (DoD)
  • NET Trial Finder: AI Clinical Trial Discovery Tool for NET- Mr. Josh Mailman -NorCal CarciNET Community
  • Moderated by Ana Maria de Jesus Acosta, MD

• • Overview of NCI Sponsored Clinical Trials in NETs
    Elise Kohn, MD. Head, Gynecologic Cancer Therapeutics, National Institutes of Health
  • Sequencing Strategies for the Management of Well-Differentiated Neuroendocrine Tumors: What the Clinicians Need to Know
    Jonathan Strosberg, MD. Professor, Moffit Cancer Center
  • Treatment Sequencing Case Presentation: Aman Chauhan, MD (case presenter)
    Panel: Dr. Jonathan Strosberg, Dr. Callisia Clarke, Dr. Erik Mittra, Dr. Ana Maria de Jesus

• • Surgical Management of Grade 3 Neuroendocrine Neoplasms
    Alexandra Gangi, MD. Director of the Gastrointestinal Tumor Program and Cancer Regional Therapies Program, Cedars Sinai Medical Center
  • Current Challenges and Management of Grade 3 Neuroendocrine Neoplasms
    Namrata (Neena) Vijayvergia, MD, Assistant Chief, Gastrointestinal Medical Oncology; Associate Professor, Department of Hematology/Oncology; Medical Director, Medical Oncology, Fox Chase Cancer Center
  • Panel Question and Answers-G3 NETs
    Moderated by Flavio G. Rocha, MD, FACS, FSSO, Professor of Surgery, Division of Surgical Oncology, Oregon Health & Science University

• • Personalize Medicine in Neuroendocrine Neoplasms: Ready for Prime Time?
    Thorvardur (Thor) R. Halfdanarson, MD, Assistant Program Director, Hematology/Oncology Fellowship Program, Mayo Clinic
  • Management of Carcinoid Heart Disease
    Heidi M. Connolly, MD, Professor of Medicine, Mayo Clinic
  • New Perspectives in the Management of Pheochromocytomas and Paragangliomas
    Karel Pacak, MD, DSc, PhD, Chief, Senior Investigator, Section on Medical Neuroendocrinology, National Institutes of Health
  • Panel Question and Answers-Special Topics in NETs
    Moderated by Heloisa Soares, MD, PhD. Associate Professor, Huntsman Cancer Center

• • Multidisciplinary Tumor Board Case: Management of Pancreas NET | | Case Presenter, Jaydira Del Rivero, MD, Physician Scientist, Developmental Therapeutics Branch, National Institutes of Health
  • Panel
  • Callisia Clarke, MD, MS, FACS, FSSO. Associate Professor and Chief, Medical College of Wisconsin
  • Thorvardur (Thor) R. Halfdanarson, MD, Assistant Program Director, Hematology/Oncology Fellowship Program, Mayo Clinic
  • Erik Mittra, MD, PhD, Nuclear Medicine Physician, Professor of Diagnostic Radiology, School of Medicine, Oregon Health & Science University
  • Flavio G. Rocha, MD, FACS, FSSO, Professor of Surgery, Division of Surgical Oncology, Oregon Health & Science University
  • Heloisa Soares, MD, PhD. Associate Professor, Huntsman Cancer Center

• • Multidisciplinary Tumor Board Case: Management of Small Bowel NET | Case Presenter, Sandy Kotiah, MD, Director of The Neuroendocrine Tumor Center, Mercy Medical Center
  • Panel
  • Jonathan M. Hernandez, MD, Chief, Surgical Oncology Program, National Institutes of Health, National Cancer Institute; Associate Professor of Surgery, Uniformed Services University of the Health Sciences
  • James Howe, MD, FACS. Professor of Surgery-Surgical Oncology and Endocrine Surgery, Iowa University
  • Alexandra Gangi, MD. Director of the Gastrointestinal Tumor Program and Cancer Regional Therapies Program, Cedars Sinai Medical Center
  • Ana Maria de Jesus-Acosta, MD, Associate Professor of Oncology, Johns Hopkins University
  • Elcin Zan, MD. Assistant Professor of Clinical Radiology, Weill Cornell Medicine

• • Multidisciplinary Tumor Board Case: Management of Hormone Syndromes | Case Presenter, Jaydira Del Rivero, MD, Physician Scientist, Developmental Therapeutics Branch, National Institutes of Health
  • Panel
  • Karel Pacak, MD, DSc, PhD, Chief, Senior Investigator, Section on Medical Neuroendocrinology, National Institutes of Health
  • Aman Chauhan, MD. Leader of the Neuroendocrine Tumor Program; Co-Director, Theragnostic Program, University of Miami
  • Julie Hallet, MD, MSC, FRCSC, Associate Scientist, Odette Cancer Center, Sunnybrook Health Sciences Centre
  • Michael Kassin, MD, Staff Clinician, National Institutes of Health
  • Heidi M. Connolly, MD, Professor of Medicine, Mayo Clinic
  • Frank I. Lin, MD, Chief, Targeted Radionuclide Therapy Section, National Institutes of Health

 

Register Now

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.75 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.75 hours of continuing nursing education credit.

Registration fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before August 30, 2023. On or after August 31, 2023, no refund will be made.

NIH and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.